{
    "Trade/Device Name(s)": [
        "Methylenedioxymethamphetamine Urine Test",
        "Morphine Urine Test",
        "Wondfo Methylenedioxymethamphetamine Urine Test",
        "Wondfo Morphine Urine Test"
    ],
    "Submitter Information": "Guangzhou Wondfo Biotech Co., Ltd.",
    "510(k) Number": "K112236",
    "Predicate Device Reference 510(k) Number(s)": [
        "K020771",
        "K022589"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LFG",
        "DJG"
    ],
    "Summary Letter Date": "August 1, 2011",
    "Summary Letter Received Date": "August 4, 2011",
    "Submission Date": "June 15, 2011",
    "Regulation Number(s)": [
        "21CFR862.3610",
        "21CFR862.3650"
    ],
    "Regulation Name(s)": [
        "Methamphetamine test system"
    ],
    "Analyte Class(es)": [
        "toxicology"
    ],
    "Analyte(s)": [
        "Methylenedioxymethamphetamine (MDMA)",
        "Morphine"
    ],
    "Specimen Type(s)": [
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [],
    "Method(s)/Technology(ies)": [
        "Immunochromatographic assay",
        "Lateral flow"
    ],
    "Methodologies": [
        "Competitive binding immunoassay",
        "Antigen-antibody immunochemistry"
    ],
    "Submission Type(s)": [
        "Test",
        "Assay"
    ],
    "Document Summary": "FDA 510(k) summary for Wondfo Methylenedioxymethamphetamine and Morphine Urine Tests using lateral flow immunochromatographic assay for qualitative detection of drugs in human urine",
    "Indications for Use Summary": "Intended for the qualitative determination of MDMA and Morphine in human urine at specific cutoff concentrations, for prescription and over-the-counter use, providing preliminary screening results.",
    "fda_folder": "Toxicology"
}